Rainmed Medical Limited Stocks

HK$ 0.24Last Updated 30.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

HK$ 44.71M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 0.24
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rainmed Medical Limited, a medical device company, focus on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microvascular resistance systems. The company offers FlashAngio caFFR System, a coronary angiography-derived fractional flow reserve measurement system, which calculates FFR values based on a three-dimensional model of the coronary arterial system restored from two angiograms and FlashAngio caIMR System, a non-invasive microcirculatory lesion diagnosis and treatment system. It is also involved in developing intelligent angiographic injection, flash robot vascular intervention navigation operation system, and flash renal denervation systems. The company was founded in 2014 and is headquartered in Suzhou, China.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks